ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs
04 January 2023 - 10:30PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that Michael Vasconcelles, MD, has been appointed
Executive Vice President, Research, Development, and Medical
Affairs.
"Following the recent approval and launch of ELAHERE™
(mirvetuximab soravtansine-gynx), we have transitioned to a
fully-integrated oncology company pursuing the global development
and commercialization of our portfolio of novel ADCs. As we look to
expand ELAHERE's label and advance our pipeline, it is essential
that we strategically align our research, development, clinical,
medical, and regulatory affairs activities at a local, regional,
and international level," said Mark Enyedy, ImmunoGen's President
and Chief Executive Officer. "I am delighted to welcome Mike to our
Executive Committee to lead the next stage of growth for these
activities. Mike brings over 30 years of experience in the
discovery, global development, and approval of transformative
cancer therapies. His strong academic and industry relationships
and knowledge of the scientific, medical, and regulatory landscape
will be integral to the efficient and effective delivery of our
portfolio to markets around the world."
Most recently, Dr. Vasconcelles has served as a Senior Advisor
to the Life Sciences team at Frazier Healthcare Partners. Prior to
that, he was the Chief Medical Officer and Head of the Medical and
Scientific Organization at Flatiron Health, a health tech company
focused on accelerating cancer research and improving patient care.
Before joining Flatiron, Dr. Vasconcelles served as Chief Medical
Officer at Unum Therapeutics, a cell and gene therapy company
developing autologous engineered T-cell products for the treatment
of cancer. He also spent several years at Takeda/Millennium, where
he was Senior Vice President and Head of the Oncology Therapy Area
Unit. Earlier in his career, Dr. Vasconcelles was Group Vice
President and the Global Therapeutic Area Head of Transplant and
Oncology at Genzyme Corporation, where he was responsible for
clinical development of the transplant and oncology portfolio and a
member of the Transplant and Oncology Business Unit management
team. Following Sanofi's acquisition of Genzyme, he joined Sanofi
Oncology as Head of Personalized Medicine and Companion
Diagnostics. Dr. Vasconcelles serves as a non-executive director of
Molecular Partners AG and Magenta Therapeutics, Inc., a Board
member of the Personalized Medicine Coalition and the Eastern New
England American Cancer Society, and a member of several Scientific
Advisory Boards within the biopharmaceutical industry. From
1996-2021, he was a faculty member at Harvard Medical School and an
associate physician at Brigham and Women's Hospital and Dana-Farber
Cancer Institute. Dr. Vasconcelles received both his BA and MD from
Northwestern University.
"This is an exhilarating next chapter for ImmunoGen as the
Company brings its first wholly-owned product to market, advances
its pipeline of ADCs through the clinic, and reinvigorates its
early-stage discovery and research efforts to drive future growth,"
said Dr. Vasconcelles. “Building on 40 years of ADC innovation, I
look forward to working with the rest of the ImmunoGen team to
drive the expansion of our platform and portfolio as we work to
bring ELAHERE, and equally groundbreaking medicines, to patients
across the globe."
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug
conjugates (ADCs) to improve outcomes for cancer patients. By
generating targeted therapies with enhanced anti-tumor activity and
favorable tolerability profiles, we aim to disrupt the progression
of cancer and offer our patients more good days. We call this our
commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
ABOUT ELAHERE (MIRVETUXIMAB SORAVTANSINE-GYNX)
ELAHERE (mirvetuximab soravtansine-gynx) is a first-in-class ADC
comprising a folate receptor alpha-binding antibody, cleavable
linker, and the maytansinoid payload DM4, a potent tubulin
inhibitor designed to kill the targeted cancer cells. Please see
full Prescribing Information, including a Boxed Warning, for
ELAHERE here.
FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. These
statements include, but are not limited to, ImmunoGen's
expectations related to the occurrence, timing, and outcome of the
Company's product and product candidates, including, but not
limited to, the commercial launch and label expansion of ELAHERE™
(mirvetuximab soravtansine-gynx), the global development and
commercialization of novel ADCs, and the progression of early-stage
discovery and research efforts. Various factors could cause
ImmunoGen's actual results to differ materially from those
discussed or implied in the forward-looking statements, and you are
cautioned not to place undue reliance on these forward-looking
statements, which are current only as of the date of this release.
Factors that could cause future results to differ materially from
such expectations include, but are not limited to: the timing and
outcome of the Company's preclinical and clinical development
processes; the difficulties inherent in the development of novel
pharmaceuticals, including uncertainties as to the timing, expense,
and results of preclinical studies, clinical trials, and regulatory
processes; the timing and outcome of the Company's anticipated
interactions with regulatory authorities; the risk that we may not
be able to obtain adequate prices and reimbursement for any
approved products, including the potential for delays or additional
difficulties for mirvetuximab; the risk that the results of the
ongoing MIRASOL trial may fail to support full approval of
mirvetuximab and, if so, that additional studies may be required;
risks and uncertainties associated with the scale and duration of
the COVID-19 pandemic and the resulting impact on ImmunoGen's
industry and business; and other factors as set forth in the
Company's Annual Report on Form 10-K filed with the Securities and
Exchange Commission on February 28, 2022, Quarterly Reports on Form
10-Q filed with the Securities and Exchange Commission on May 6,
2022, August 1, 2022 and November 4, 2022, and other reports filed
with the Securities and Exchange Commission. The forward-looking
statements in this press release speak only as of the date of this
press release. We undertake no obligation to update any
forward-looking statement, whether as a result of new information,
future developments, or otherwise, except as may be required by
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230104005094/en/
INVESTOR RELATIONS ImmunoGen Anabel Chan 781-895-0600
anabel.chan@immunogen.com
MEDIA ImmunoGen Courtney O'Konek 781-895-0600
courtney.okonek@immunogen.com OR FTI Consulting Robert Stanislaro
212-850-5657 robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024